GLP-BARI-VAN

Recruiting

Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults With Obesity

Comparison of Two-Year Weight-Loss Effectiveness of GLP-1 Receptor Agonists and Laparoscopic Sleeve Gastrectomy in the Treatment of Obesity: An Ambispective Propensity Score-Matched Cohort Study

Lead sponsor

Yuzuncu Yil University

Assets

Liraglutide / Semaglutide

Listed sites

Recruiting sites

Estimated enrollment

200

Study population

Obesity / overweight

Eligibility highlights

Primary endpoint

•Percentage of Total Body Weight Loss

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07901777

Org study IDGLP-BARI-VAN

Timeline

Milestones

Study start2026-09-15actual

Study first posted2026-10-28actual

Last update posted2026-10-28actual

Primary completion2028-09-15estimated

Study completion2028-11-15estimated

Assets

Investigational agents

Liraglutide Semaglutide

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Sampling methodNon probability sample

Study population text

Adults aged 18 years or older receiving treatment for obesity or overweight at the Obesity Center of Van Training and Research Hospital, Türkiye. The prospective cohort will include consecutive eligible patients initiating GLP-1 receptor agonist therapy for weight management as part of routine clinical care. The retrospective cohort will include eligible patients who underwent primary laparoscopic sleeve gastrectomy for obesity at the same center between January 1, 2020, and January 1, 2026. Treatment decisions are made independently of study participation. The cohorts will be matched using propensity scores based on pretreatment demographic and clinical characteristics.

Inclusion criteria

GLP-1 Receptor Agonist Cohort:

•Age 18 years or older at treatment initiation.

•Initiation of a GLP-1 receptor agonist for obesity or overweight as part of routine clinical care.

•Available baseline height and body weight measurements.

•Willingness to attend at least one follow-up assessment.

•Ability to comply with the center's standard follow-up program.

•Provision of written informed consent.

Laparoscopic Sleeve Gastrectomy Cohort:

•Age 18 years or older at surgery.

•Primary laparoscopic sleeve gastrectomy for obesity performed at the study center between January 1, 2020, and January 1, 2026.

•Available preoperative height, body weight, and body mass index measurements.

•Available demographic and baseline clinical data.

•At least one documented postoperative body weight measurement. Availability of a 24-month weight measurement is preferred for the primary comparison.

Exclusion criteria

Both Cohorts:

•Bariatric or metabolic surgery before the index treatment.

•Revisional bariatric surgery as the index treatment.

•Active malignancy or a serious systemic disease substantially affecting body weight.

•Pregnancy or breastfeeding at the index treatment.

•Uncontrolled endocrine disease that may cause weight loss.

•Missing baseline height or body weight measurements.

•Recent participation in another intensive weight-loss program before the index treatment.

•Concurrent use of another anti-obesity treatment that could substantially affect study outcomes.

•Inability to reliably verify study data.

GLP-1 Receptor Agonist Cohort:

•Short-term GLP-1 receptor agonist use for an indication other than weight management.

•Medication prescribed but never administered.

Laparoscopic Sleeve Gastrectomy Cohort:

•Sleeve gastrectomy performed concurrently with another bariatric procedure.

•Sleeve gastrectomy performed for an indication other than primary obesity treatment.

Endpoints (21)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Other (unclassified)

Safety / tolerability / PK

Other clinical outcomes

Weight & body composition

9 endpoints

Primary/protocol endpoint

Percentage of Total Body Weight Loss at 24 Months

Time frame:24 months after GLP-1 receptor agonist treatment initiation or sleeve gastrectomy.

descriptive

Secondary/protocol endpoint

Percentage of Total Body Weight Loss at Earlier Follow-Up Visits

Time frame:At 1, 3, 6, and 12 months after treatment initiation.

descriptive

Secondary/protocol endpoint

Change in Body Weight

Time frame:Baseline to months 1, 3, 6, 12, and 24.

change from baseline, improvement

Secondary/protocol endpoint

Change in Body Mass Index

Time frame:Baseline to months 1, 3, 6, 12, and 24.

change from baseline, improvement

Secondary/protocol endpoint

Percentage of Participants Achieving at Least 5% Total Body Weight Loss

Time frame:At months 1, 3, 6, 12, and 24.

threshold achievement, improvement

Secondary/protocol endpoint

Percentage of Participants Achieving at Least 10% Total Body Weight Loss

Time frame:At months 1, 3, 6, 12, and 24.

threshold achievement, improvement

Secondary/protocol endpoint

Percentage of Participants Achieving at Least 15% Total Body Weight Loss

Time frame:At months 1, 3, 6, 12, and 24.

threshold achievement, improvement

Secondary/protocol endpoint

Percentage of Participants Achieving at Least 20% Total Body Weight Loss

Time frame:At months 1, 3, 6, 12, and 24.

threshold achievement, improvement

Secondary/protocol endpoint

Percentage of Participants Achieving at Least 25% Total Body Weight Loss

Time frame:At months 1, 3, 6, 12, and 24.

threshold achievement, improvement

Safety / tolerability / PK

5 endpoints

Secondary/protocol endpoint

Percentage of Participants Experiencing Any Adverse Event During GLP-1 Therapy

Time frame:From the first medication dose through 24 months.

threshold achievement, event

Secondary/protocol endpoint

Percentage of Participants Experiencing Gastrointestinal Adverse Events During GLP-1 Therapy

Time frame:From the first medication dose through 24 months.

threshold achievement, event

Secondary/protocol endpoint

Percentage of Participants Experiencing Serious Adverse Events During GLP-1 Therapy

Time frame:From the first medication dose through 24 months.

threshold achievement, event

Secondary/protocol endpoint

Percentage of Participants Requiring GLP-1 Dose Reduction Due to Adverse Events

Time frame:From treatment initiation through 24 months.

threshold achievement, event

Secondary/protocol endpoint

Percentage of Participants Permanently Discontinuing GLP-1 Therapy Due to Adverse Events

Time frame:From treatment initiation through 24 months.

threshold achievement, event

Other clinical outcomes

1 endpoint

Secondary/protocol endpoint

Improvement or Remission of Obesity-Related Comorbidities

Time frame:At months 3, 6, 12, and 24.

descriptive

Other (unclassified)

6 endpoints

Secondary/protocol endpoint/low confidence

Percentage of Participants Permanently Discontinuing GLP-1 Therapy for Any Reason

Time frame:From treatment initiation through 24 months.

threshold achievement, improvement

Secondary/protocol endpoint/low confidence

Duration of GLP-1 Treatment Persistence

Time frame:From treatment initiation through 24 months.

ratio, improvement

Secondary/protocol endpoint/low confidence

Percentage of Participants With Emergency Department Visits

Time frame:From treatment initiation through 24 months.

threshold achievement, improvement

Secondary/protocol endpoint/low confidence

Percentage of Participants With Hospital Admissions

Time frame:From treatment initiation through 24 months.

threshold achievement, improvement

Secondary/protocol endpoint/low confidence

Percentage of Participants With Early Surgical Complications

Time frame:Within 30 days after sleeve gastrectomy.

threshold achievement, improvement

Secondary/protocol endpoint/low confidence

Percentage of Participants With Late Surgical Complications

Time frame:From postoperative day 31 through 24 months.

threshold achievement, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateNovember 5, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the November 5, 2026 snapshot.